about
Combination regimens of radiation therapy and therapeutic cancer vaccines: mechanisms and opportunitiesRadiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactionsRadiation-induced survival responses promote immunogenic modulation to enhance immunotherapy in combinatorial regimens.Defining molecular signature of pro-immunogenic radiotherapy targets in human prostate cancer cells.Combination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and mediates local and distal tumor regression.Defining the molecular signature of chemotherapy-mediated lung tumor phenotype modulation and increased susceptibility to T-cell killing.Improving clinical benefit for prostate cancer patients through the combination of androgen deprivation and immunotherapy.The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitorsVaccine-mediated immunotherapy directed against a transcription factor driving the metastatic process.Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death.Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.Androgen deprivation therapy sensitizes triple negative breast cancer cells to immune-mediated lysis through androgen receptor independent modulation of osteoprotegerin.Attacking malignant cells that survive therapy: Exploiting immunogenic modulation.Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets.Sublethal exposure to alpha radiation (223Ra dichloride) enhances various carcinomas' sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation.Cancer vaccines targeting carcinoembryonic antigen: state-of-the-art and future promise.Rationale for IL-15 superagonists in cancer immunotherapyTwo may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancerCooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer TherapyIf we build it they will come: targeting the immune response to breast cancerEfficient Tumor Clearance and Diversified Immunity through Neoepitope Vaccines and Combinatorial ImmunotherapyFunctional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist
P50
Q26851710-C12B60C9-5FE5-45EF-A0CE-B66C8A5B4CC5Q33627023-8C6C9517-C634-49AB-9A66-97371665D4F2Q33878572-C22F37B0-5C06-40B1-9356-4483A8339FA0Q34438000-13C91C42-5E3F-4363-9D53-7FA4FCA91FF7Q34876404-A687634A-0121-44D5-BD31-31C5B86607A9Q35752182-BD65375A-408E-4946-B834-09BB9FFC8FFAQ35799330-EB7AF7B2-53DB-4B9C-BC6E-B069C910D024Q35975387-40BA30B4-F913-4576-BF8A-835AE4A35317Q36420021-C96BC3BC-B6F2-4806-B6BC-A05E9FD563CCQ36874767-CE28EFF0-7324-4FC2-AC0E-03F0A42D05F1Q36946516-F0D8382A-3F8C-4704-AF9E-DEFE08DBFF6FQ37269053-2B068E01-75A4-4B8B-BF50-DCA8A3CA0BCAQ37515914-5495795A-75C7-47C4-836A-2B8406B9A396Q37650735-1C19676D-1E83-4BF1-B6DC-4161F16BED84Q37686296-DB8DE07D-3482-4580-B7B4-384773F95129Q38113267-56DECB7B-9269-4B30-84F2-2AA83557FF12Q90227161-B91CC733-AB27-4759-BDC9-BD412651F263Q90644277-CF606118-30D8-4161-B40B-B9D6364957A4Q90910007-9410CE33-2D30-499F-8850-0D6A1BCEEB5DQ91178274-4074FCAB-07A7-4C5E-929C-5C2E6D4A162CQ91774823-631CFB20-00E4-4876-AAA7-F54EF90EEF06Q92024784-EC70E3EC-4335-4AF1-8EA4-FC407A8E17C8
P50
description
researcher ORCID ID = 0000-0002-2392-8122
@en
wetenschapper
@nl
name
Sofia R Gameiro
@ast
Sofia R Gameiro
@en
Sofia R Gameiro
@es
Sofia R Gameiro
@nl
type
label
Sofia R Gameiro
@ast
Sofia R Gameiro
@en
Sofia R Gameiro
@es
Sofia R Gameiro
@nl
prefLabel
Sofia R Gameiro
@ast
Sofia R Gameiro
@en
Sofia R Gameiro
@es
Sofia R Gameiro
@nl
P106
P1153
54896026900
P31
P496
0000-0002-2392-8122